Table 1 HLA-matched patient characteristics, donor cells, and outcomes.

ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; IgA, IgA nephropathy; DM, diabetes; SLE, systemic lupus erythematosus; PKD, polycystic kidney disease; CIN, chronic interstitial nephritis.

Patient no.Age at Tx/sexESRD diagnosisCD34+ cell dose
(×106/kg)
CD3+ cell dose
(×106/kg)
SCr: Last
measure
(mg/dl)
Duration of
follow-up
(months)
Duration off IS
drugs (months)
148/MUnknown811.3241*36
239/FFSGS811.021570
324/MDysplasia1311.621520
452/MUnknown511.13137119
534/MIgA1311.37135129
661/FDM1211.301300
723/FSLE17105.70‡,§119*12
833/MReflux1710.75124122
929/FUnknown1811.051210
1052/FPKD1410.90120109
1137/FIgA1412.40§11163
1236/FPKD1011.20107101
1326/MUnknown611.2010088
1422/FUnknown1410.8610088
1540/FIgA1011.139848||
1642/MType 1 DM611.1334*23
1730/MCIN615.77‡,§7152
1839/MIgA911.298071
1929/MIgA1211.267768
2045/FUnknown1411.007259
2162/FIgA1210.746860
2254/FAlport411.006550
2349/MDM611.035541
2428/MReflux611.556338
2537/MIgA711.304834
2643/MUnknown1411.04460
2738/FIgA610.803623
2844/MIgA911.633522
2930/MIgA1151.072714
Median (months)8048

*Deceased.

†No loss of chimerism.

‡SCr, serum creatinine concentration just before dialysis.

§Relapse of kidney disease without rejection.

||Acute rejection at four years off IS drug, returned to IS drug therapy. Duration of follow-up is to last SCr test. Patient nos. 7 and 29 were given 10 × 106 and 5 × 106 T cells/kg to increase chimerism levels. Patient nos. 1, 7, and 16 died in association with coronary artery disease, lupus-related stroke, and complications of morbid obesity and diabetes mellitus, respectively.